10-Q: Dalrada Reports Q3 Loss Amidst Liquidity Concerns

Dalrada Financial Corporation reported a net loss of $4.2 million for Q3 2025, with significant working capital deficit and ongoing going concern doubts, despite revenue growth in its Climate Technology segment.

Summary

• Dalrada Financial Corporation reported a net loss of $4,222,529 for the three months ended March 31, 2025, an improvement from a net loss of $9,272,142 in the prior year period.
• For the nine months ended March 31, 2025, the net loss was $17,768,606, compared to $19,550,458 for the same period in 2024.
• Total revenues for the three months ended March 31, 2025, increased to $4,574,276 from $3,428,733 in the prior year, primarily driven by the Dalrada Climate Technology segment.
• Total revenues for the nine months ended March 31, 2025, decreased to $13,719,789 from $14,524,575 in the prior year.
• The company's working capital deficit significantly worsened to $15,541,708 as of March 31, 2025, from $7,085,306 as of June 30, 2024.
• Cash and cash equivalents decreased to $98,841 as of March 31, 2025, from $501,927 as of June 30, 2024.
• The company's ability to continue as a going concern is dependent on successful financing and growing profitable subsidiaries.
• Acquired Grand Entrances on August 21, 2024, for $100 cash, assumption of liabilities, and a 20% EBITDA earnout over 3 years.
• Acquired IV Services, LLC (dba Genefic Infusion Rx) on May 13, 2024, for cash and assumption of liabilities totaling $156,926.
• Several legal proceedings are ongoing, including cross-complaints for breach of contract and tortious interference, with some cases settled or dismissed.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, a substantial working capital deficit, and an explicit going concern warning. While net loss improved and one segment showed strong revenue growth, the overall financial health is highly precarious, with heavy reliance on related party financing and ineffective internal controls. Numerous ongoing legal battles add to the uncertainty.

Positives

• Net loss for the three months ended March 31, 2025, improved to $4,222,529 from $9,272,142 in the prior year period.
• Net loss for the nine months ended March 31, 2025, improved to $17,768,606 from $19,550,458 in the prior year period.
• Total revenues for the three months ended March 31, 2025, increased by 33.4% to $4,574,276.
• Dalrada Climate Technology segment revenue increased by 528.2% for the three months and 92.6% for the nine months ended March 31, 2025, due to Bothof Brothers securing multiple construction opportunities.
• Gross profit for the nine months ended March 31, 2025, increased significantly to $3,403,008 from $1,319,536 in the prior year.
• Operating expenses decreased by 6.0% for the nine months ended March 31, 2025, to $18,117,260.
• Legal proceedings against Vivera Pharmaceuticals JV and Kroger Specialty Pharmacy LLC were dismissed or settled.

Negatives

• The company has a significant negative working capital of $15,541,708 as of March 31, 2025, a substantial increase from $7,085,306 on June 30, 2024.
• Cash and cash equivalents decreased significantly to $98,841 as of March 31, 2025, from $501,927 as of June 30, 2024.
• Total liabilities increased substantially to $33,726,976 as of March 31, 2025, from $19,718,940 as of June 30, 2024.
• Stockholders' equity shifted to a deficit of $11,979,197 as of March 31, 2025, from a positive equity of $3,346,107 as of June 30, 2024.
• Genefic segment revenue decreased by 39.6% for the three months and 11.1% for the nine months ended March 31, 2025, due to reduced sales in Genefic Specialty Pharmacy.
• Dalrada Precision Manufacturing segment revenue decreased by 57.9% for the three months and 84.4% for the nine months ended March 31, 2025, due to decreased sales activity.
• Dalrada Technologies segment revenue decreased by 26.1% for the three months and 7.7% for the nine months ended March 31, 2025, due to completing customer contracts.
• Cash used in operating activities increased to $6,143,953 for the nine months ended March 31, 2025, from $5,660,542 in the prior year.
• Accounts payable and accrued liabilities to related parties increased dramatically to $9,557,851 as of March 31, 2025, from $136,976 as of June 30, 2024.
• Disclosure controls and procedures were not effective as of March 31, 2025.

Risks

• The company's net loss and limited working capital raise substantial doubt about its ability to continue as a going concern.
• Continuation as a going concern is dependent upon successful financing through equity and/or debt investors and growing profitable subsidiaries.
• The company expects to incur additional losses in the foreseeable future.
• There is no assurance that additional financing will be available or on acceptable terms, leading to potential inability to execute business plans.
• Increased costs are being incurred as a result of being a publicly traded company, including legal, accounting, and compliance expenses.
• Ineffective disclosure controls and procedures pose a risk to the reliability of financial reporting and compliance with SEC rules.
• Ongoing legal proceedings, including significant cross-complaints for breach of contract and tortious interference, could result in substantial financial liabilities or impact business operations.
• The EIDL loan is technically in default due to a change in ownership without SBA consent, posing a risk of acceleration or other penalties.

Future Outlook

The company's continuation as a going concern is dependent upon successful financing through equity and/or debt investors and growing profitable subsidiaries. Management plans to support operations by raising capital and accelerating sales and marketing efforts for high-margin products and services. The company anticipates needing additional liquidity over the next twelve months to fund operations, expand subsidiaries, and continue commercialization efforts.

Management Comments

• Our net loss and limited working capital raise substantial doubt about our ability to continue as a going concern.
• We will be required to raise substantial capital to fund our capital expenditures, working capital, and other cash requirements.
• We will continue to rely on related parties and seek other financing to complete our business plans.

Industry Context

Dalrada operates across diverse sectors including healthcare, climate technology, precision manufacturing, and general technology. While the Dalrada Climate Technology segment, particularly through Bothof Brothers, is experiencing significant revenue growth due to construction opportunities, other segments like Genefic Specialty Pharmacy and Dalrada Precision Manufacturing are facing decreased sales activity. This indicates a mixed performance across its diversified portfolio, with some areas capitalizing on market demand (e.g., construction, clean energy) while others contend with reduced activity or contract completion.

Corporate Governance

Legal Proceedings

• Lawsuit filed by Genefic Products (Dalrada Health) against Vivera Pharmaceuticals, Inc. and Paul Edalat for misappropriation of funds ($2,104,509) was dismissed on January 13, 2025.
• Lawsuits/preliminary injunctions filed by Kroger Specialty Pharmacy LLC against Genefic Specialty Pharmacy and two employees were settled and dismissed on March 19, 2025.
• Asset Group, Inc. filed a breach of contract suit against Dalrada Health Products (DHP) for $3,240,000; DHP filed a cross-complaint for tortious interference with contractual business relations, seeking $3,240,000 in lost profits. Jury trial scheduled for September 19, 2025.
• MDIQ filed a breach of contract suit against Dalrada Financial Corporation (DFCO) for unpaid invoices; DFCO is counter-suing for approximately $2,000,000 of unpaid claims. No trial date set.
• DFCO filed a lawsuit against Simon Gray and DePrey Company for breach of contract and intentional interference with contractual relationships. No trial date set.
• DFCO filed a lawsuit against Stuart Cox (seller of Likido) for fraud, breach of contract, and unjust enrichment. Settlement negotiations are ongoing.
• DFCO filed a lawsuit against William Bonar, Samantha and Ian MacKenzie, Jillian Hughes, and Marion Bonar (former employees/directors of UK subsidiaries) for fraud, tortious interference, and misappropriation of trade secrets. No trial date set.
• FFF Enterprises filed a lawsuit against Genefic, Inc. and DFCO for alleged breach of a service agreement, demanding $564,743.48. Settlement negotiations are ongoing.
• A former employee filed a complaint alleging numerous labor law violations after being laid off. A jury trial is scheduled for October 10, 2025.
• Lamie RB Investments, LLC filed a suit for breach of a lease contract with Genefic, Inc., seeking damages equal to the lease term. Genefic, Inc. filed a motion to dismiss.
• DFCO filed a lawsuit against Wells Fargo on July 7, 2025, for releasing Pala funds while the account was frozen for litigation.

Related Party Transactions

• The company received cash funding or expenses paid on its behalf from related parties totaling $1,535,595 for the three months and $3,957,311 for the nine months ended March 31, 2025.
• Promissory notes were created quarterly for these related party fundings, with remaining amounts included in accounts payable related parties.
• Accounts payable and accrued liabilities related parties increased significantly to $9,557,851 as of March 31, 2025, from $136,976 as of June 30, 2024.
• Related party revenues for the nine months ended March 31, 2025, totaled $1,007,656, primarily from Bothof Brothers ($1,007,656).
• Conversion of related party debt principal and interest into preferred stock amounted to $17,243,235 for the nine months ended March 31, 2025.
• The EIDL loan is technically in default due to a change in ownership without SBA prior written consent, and the company has contacted the SBA regarding the transfer of ownership.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing equity sales and conversions of debt into common stock, as well as the risk of substantial losses and the going concern warning.
• Employees and consultants are compensated with stock-based compensation, but the company's financial instability could impact job security and the value of equity awards.
• Creditors, particularly related parties, are providing substantial financing, indicating a high level of reliance on these relationships, but also exposing them to the company's financial risks.
• Customers of Dalrada Climate Technology (Bothof Brothers) may benefit from increased construction opportunities, while customers of Genefic Specialty Pharmacy and Dalrada Precision Manufacturing may experience reduced service or product availability due to decreased sales activity.
• Regulatory bodies (SEC) are impacted by the company's disclosure controls and procedures being deemed ineffective, requiring close monitoring and potential enforcement actions.

Next Steps

• Obtain operational liquidity through collection of outstanding accounts receivable from medical insurance providers, Medicare, and pharmaceutical sales.
• Accelerate sales of DCT commercial and residential heat pumps.
• Continue ongoing projects through Bothof Brothers, Dalrada Technology Spain, and Deposition Technologies.
• Obtain additional financing through equity and/or debt investors.
• Double the class size for the DCI RN nursing program in 2025.
• Continue discovery in the Asset Group, Inc. lawsuit, with a jury trial scheduled for September 19, 2025.
• Continue discovery in the MDIQ lawsuit, with the company in the process of counter-suing for $2,000,000.
• Continue discovery in the Simon Gray and DePrey Company lawsuit.
• Continue settlement negotiations in the Stuart Cox (Likido) lawsuit.
• Continue discovery in the William Bonar et al. lawsuit regarding UK subsidiaries.
• Continue settlement negotiations in the FFF Enterprises lawsuit.
• Conduct in-depth discovery for the former employee labor law violations lawsuit, with a jury trial scheduled for October 10, 2025.
• Pursue motion to dismiss in the Lamie RB Investments, LLC lawsuit.

Key Dates

Recommendation

The filing presents a highly concerning financial picture. The company explicitly states 'substantial doubt about the Company’s ability to continue as a going concern' due to significant net losses and a rapidly worsening working capital deficit. Cash reserves are critically low, and total liabilities have surged. While some segments show revenue growth, the overall financial instability, heavy reliance on related party financing, and ineffective internal controls indicate severe operational and financial risks. The numerous ongoing legal proceedings add further uncertainty and potential liabilities. A seasoned investor would view these factors as strong indicators of a company in distress, making it a 'strong sell' due to the high risk of capital loss and potential bankruptcy.

Keywords

Dalrada Financial Corporation, DFCO, 10-Q, Quarterly Report, Financial Results, Net Loss, Working Capital Deficit, Going Concern, SEC Filing, Healthcare, Climate Technology, Precision Manufacturing, Technology Services, Acquisitions, Legal Proceedings, Related Party Transactions, Convertible Preferred Stock, Cash Flow, Operating Expenses, Revenue Growth, Bothof Brothers, Genefic, Likido, DepTec, Prakat